What made Corvus stock double on Tuesday and is it sustainable?
Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib”...
Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib”...
Apple stock (NASDAQ: AAPL) slid nearly 3% on Tuesday, even as Evercore and Citi issued constructive notes ahead of the...
BigBear.ai (NYSE: BBAI stock) tumbled on Tuesday after Pomerantz LLP, a prominent securities law firm, announced it is investigating whether...
Netflix (NASDAQ: NFLX) shares are trending down in after-hours after the streaming behemoth reported its financials for the fourth quarter...
Asian financial markets remained under pressure on Wednesday as geopolitical tensions linked to US President Donald Trump’s comments on Greenland...
The Tesco share price pulled back and moved into a correction, falling by 11% from its highest level in November...
ROME — Italian fashion designer Valentino Garavani has died, his foundation said Monday. Usually known only by his first name,...
European capitals are weighing their response to President Donald Trump’s latest tariff threat, this time tied to his controversial push...
The Nikkei 225 Index retreated by over 1.2% on Tuesday, continuing a downtrend that has been going on in the...
Pop Mart’s share price jumped by over 8% on Tuesday, its best performance in five months, as investors cheered its...
Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.